Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov 11;111(10):1909-16.
doi: 10.1038/bjc.2014.503. Epub 2014 Oct 28.

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

A B Suttle  1 , H A Ball  2 , M Molimard  3 , T E Hutson  4 , C Carpenter  5 , D Rajagopalan  2 , Y Lin  2 , S Swann  2 , R Amado  2 , L Pandite  1
Affiliations

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

A B Suttle et al. Br J Cancer. .

Erratum in

  • Br J Cancer. 2014 Dec 9;111(12):2383

Abstract

Background: Pazopanib, an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR)/c-Kit, is approved in locally advanced/metastatic renal cell carcinoma (RCC).

Methods: Data from trials in advanced solid tumours and advanced/metastatic RCC were used to explore the relationships between plasma pazopanib concentrations and biomarker changes, safety, and efficacy. Initially, the relationships between pharmacokinetic parameters and increased blood pressure were investigated, followed by analysis of steady-state trough concentration (Cτ) and sVEGFR2, safety, progression-free survival (PFS), response rate, and tumour shrinkage. Efficacy/safety end points were compared at Cτ decile boundaries.

Results: Strong correlation between increased blood pressure and Cτ was observed (r(2)=0.91), whereas weak correlation was observed between Cτ and decline from baseline in sVEGFR2 (r(2)=0.27). Cτ threshold of >20.5 μg ml(-1) was associated with improved efficacy (PFS, P<0.004; tumour shrinkage, P<0.001), but there was no appreciable benefit in absolute PFS or tumour shrinkage from Cτ >20.5 μg ml(-1). However, the association of Cτ with certain adverse events, particularly hand-foot syndrome, was continuous over the entire Cτ range.

Conclusions: The threshold concentration for efficacy overlaps with concentrations at which toxicity occurs, although some toxicities increase over the entire Cτ range. Monitoring Cτ may optimise systemic exposure to improve clinical benefit and decrease the risk of certain adverse events.

Trial registration: ClinicalTrials.gov NCT00334282.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pazopanib exposure and blood pressure. Relationship, in patients with solid tumours, between the occurrence of a significant increase in blood pressure (BP) and steady-state plasma pazopanib AUC (A), Cmax (B), and Cτ (C); relationship between steady-state AUC and Cτ (D). Open circles represent individual observations (0=no significant increase; 1=significant increase) and closed circles represent the proportion of patients with a significant increase in blood pressure within each plasma pazopanib Cτ quintile range. The thick line represents the plasma pazopanib Cτ quintile range.
Figure 2
Figure 2
Steady-state plasma pazopanib concentration and clinical response. The Kaplan–Meier curves showing PFS (A) and empirical cumulative distribution function (CDF) of maximum decrease from baseline in tumour size (B) for patients with week 4 predose steady-state plasma pazopanib concentration (Cτ) ⩽20.5 μg ml−1 (black) and >20.5 μg ml−1 (red).
Figure 3
Figure 3
Distribution of predose steady-state plasma pazopanib concentrations (Cτ).
See this image and copyright information in PMC

References

    1. Australian Government Department of Health and Ageing 2010. Drugs designated as orphan drugs: Pazopanib (PATORMA) http://www.tga.gov.au/industry/pm-orphan-drugs.htm .
    1. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008;26 (11:1810–1816. - PubMed
    1. Cacheux W, Boisserie T, Staudacher L, Vignaux O, Dousset B, Soubrane O, Terris B, Mateus C, Chaussade S, Goldwasser F. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol. 2008;19 (9:1659–1661. - PubMed
    1. Deng Y, Sychterz C, Suttle AB, Dar MM, Bershas D, Negash K, Qian Y, Chen EP, Gorycki PD, Ho MY. Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013;43 (5:443–453. - PubMed
    1. Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 2007;5:32. - PMC - PubMed

Publication types

MeSH terms

Associated data